Results 101 to 110 of about 104,011 (317)

ERP evidence suggests executive dysfunction in ecstasy polydrug users [PDF]

, 2013
Background: Deficits in executive functions such as access to semantic/long-term memory have been shown in ecstasy users in previous research. Equally, there have been many reports of equivocal findings in this area.
A Gamma, A Miyake, A Pazos, AC Parrott, AG Verstraete, AJ Saykin, AP Burgess, B Kopp, C Casco, C Montgomery, C Montgomery, C Montgomery, C Montgomery, C Montgomery, C Whitney, C. A. Roberts, C. Montgomery, D Badre, D Davison, DE Hinkle, DM McDowell, DT Stuss, E Jefferies, EM Bekker, F. Tames, G Jager, G Kanayama, HC Fox, J Cole, J. E. Fisk, JA Horne, JE Fisk, JH Halpern, JR Folstein, M Terman, MA Wetherell, MJ Morgan, N Yeung, PN Murphy, RL Carhart-Harris, RM Ruff, RM Shiffrin, S Bhattachary, S Mejias, S Nieuwenhuis, S Rossi, S Sola de, S Suwazono, S. H. Fairclough, SJ Luck, SL Rosell, T Akerstedt, V Veen van, W Ritter   +53 more
core   +1 more source

Diagnostic Impact of Liver Biopsy Among Antinuclear Antibody Positive Individuals With Mild Liver Enzyme Elevation

Alimentary Pharmacology &Therapeutics, EarlyView.
In ANA‐positive patients with suspected autoimmune hepatitis (AIH), liver biopsy rarely altered therapeutic management when alanine aminotransferase (ALT) was below 101 U/L and cirrhosis was absent. These findings suggest that biopsy may be safely deferred in this low‐risk group.
David Mehdi Asgher Niazi, Alphonse Charbel, Jan Pfeiffenberger, Uta Merle, Jessica Seessle, Theresa Wenz, Christa Flechtenmacher, Patrick Michl, Conrad Rauber   +8 more
wiley   +1 more source

Preclinical models for evaluating psychedelics in the treatment of major depressive disorder

British Journal of Pharmacology, EarlyView.
Psychedelic drugs have seen a resurgence in interest as a next generation of psychiatric medicines with potential as rapid‐acting antidepressants (RAADs). Despite promising early clinical trials, the mechanisms which underlie the effects of psychedelics are poorly understood.
Laith Alexander, Dasha Anderson, Luke Baxter, Matthew Claydon, James Rucker, Emma S. J. Robinson   +5 more
wiley   +1 more source

The N Terminus of Monoamine Transporters Is a Lever Required for the Action of Amphetamines*

Journal of Biological Chemistry, 2010
The serotonin transporter (SERT) terminates neurotransmission by removing serotonin from the synaptic cleft. In addition, it is the site of action of antidepressants (which block the transporter) and of amphetamines (which induce substrate efflux).
S. Sucic, Stefan Dallinger, Barbara Zdrazil, Rene Weissensteiner, T. N. Jørgensen, M. Holy, O. Kudlacek, Stefan Seidel, J. Cha, U. Gether, A. Newman, G. Ecker, M. Freissmuth, H. Sitte   +13 more
semanticscholar   +1 more source

The Use of Amphetamines for Improving Cognitive Impairment in Patients with Multiple Sclerosis [PDF]

Background: Multiple sclerosis (MS) is an autoimmune disorder that results in debilitating cognitive impairment in 40-65% of patients. There are no current treatments for this symptom of MS.
Kum, Hayley
core   +1 more source

Psychedelics, entactogens and psychoplastogens for depression and related disorders

British Journal of Pharmacology, EarlyView.
Currently, the most actively investigated rapidly acting antidepressants, anxiolytics and/or anti PTSD agents, include psychedelics e.g. psilocybin, LSD, N,N‐dimethyltryptamine, ayahuasca; non‐hallucinogenic entactogens, e.g. MDMA; psychoplastogens which rapidly promote neuroplasticity, e.g.
Daniel Hoyer
wiley   +1 more source

Amphetamines [PDF]

The Vernal Pool, 2018
Visual art.
openaire   +3 more sources

Global Overview of Drug Demand and Supply: Latest Trends, Cross-cutting Issues [PDF]

, 2017
An estimated quarter of a billion people, or around 5 per cent of the global adult population, used drugs at least once in 2015. Even more worrisome is the fact that about 29.5 million of those drug users, or 0.6 per cent of the global adult population ...

core  

Evidence that 5‐HT2A receptor signalling efficacy and not biased agonism differentiates serotonergic psychedelic from non‐psychedelic drugs

British Journal of Pharmacology, EarlyView.
Background and Purpose Serotonergic psychedelic drugs are under investigation as therapies for various psychiatric disorders, including major depression. Although serotonergic psychedelic drugs are 5‐HT2A receptor agonists, some such agonists are not psychedelic, potentially due to differences in 5‐HT2A receptor ligand bias or signalling efficacy. Here,
Aurelija Ippolito, Sridhar Vasudevan, Shaun Hurley, Gary Gilmour, Frederick Westhorpe, Grant Churchill, Trevor Sharp   +6 more
wiley   +1 more source

Recreational drugs and outcomes in trauma patients

Journal of Emergencies, Trauma and Shock, 2019
Objective: The objective of the study is to determine if marijuana, methamphetamine, or cocaine is associated with worse outcomes following trauma. Methods: A retrospective cross-sectional study was conducted on 731 trauma patients.
Quinn Fujii, Andrew McCague
doaj   +1 more source